Immunomodulatory Therapies Flashcards Preview

Laura Path Recall > Immunomodulatory Therapies > Flashcards

Flashcards in Immunomodulatory Therapies Deck (79):
1

MOA: Corticosteroids

Inhibit phospholipase A2

2

Inhibit phospholipase A2

MOA: Corticosteroids

3

MOA: Tacrolimus

Calcinurin Inhibitor, block cytokine transcription

4

MOA: Cyclosporin

Calcinurin Inhibitor, block cytokine transcription

5

Calcinurin Inhibitor, block cytokine transcription (x2)

Tacrolimus, cyclosporin

6

MOA: Tofacitinib

JAK inhibitor, inhibits cell signalling

7

JAK inhibitor, inhibits cell signalling

Tofacitinib

8

MOA: Sirolimus

blocks clonal T cell proliferation

9

MOA: Apremilast

PDE4 inhibitor, inhibits cell signalling

10

PDE4 inhibitor, inhibits cell signalling

Apremilast

11

MOA: Basiliximab

ab vs. CD25, anti-IL2

12

ab against CD25 on IL-2 receptor (x2)

Basiliximab, Daclizumab

13

Indication: Basiliximab, Daclizumab

Rejection prophylaxis in transplant

14

Indication: Tacrolimus

Rejection prophylaxis in transplant

15

Indication: Cyclosporin

Rejection prophylaxis in transplant

16

Indication: Sirolimus

Rejection prophylaxis in transplant

17

Indication: Tofacitinib

Rheumatoid arthritis

18

Indication: Apremilast

Psoriasis

19

Indication: Abatacept

Rheumatoid arthritis

20

MOA: Abatacept

CTLA4-Ig fusion protein, (directed against cell surface antigens to ↓T cell activation)

21

CTLA4-Ig fusion protein, (directed against cell surface antigens to ↓T cell activation)

Abatacept

22

MOA: Rituximab

ab vs. CD20, depletes mature B cells

23

ab vs. CD20, depletes mature B cells

Rituximab

24

Indications: Rituximab

RhA, SLE, lymphoma

25

MOA: Toclizumab

ab vs. IL-6 receptor, ↓activation of neuts, B/T cells, macrophages

26

ab vs. IL-6 receptor, ↓activation of neuts, B/T cells, macrophages

Toclizumab

27

Indications: Toclizumab

Castleman's disease, Rheumatoid arthritis

28

MOA: Natalizumab

ab vs. a4 integrin, ↓T cell migration

29

ab vs. a4 integrin, ↓T cell migration

Natalizumab

30

Indications: Natalizumab

active MS

31

MOA: Daclizumab

ab against CD25 on IL-2 receptor

32

MOA: Alemtuzumab

ab vs. CD52, ↓lymphocytes

33

ab vs. CD52, ↓lymphocytes

Alemtuzumab

34

Indications: Alemtuzumab

MS, CLL

35

MOA: Muromonab-CD3

Blocks CD3 on T cell

36

Blocks CD3 on T cell

Muromonab-CD3

37

Indications: Muromonab-CD3

Active transplant rejection

38

MOA: Efalizumab

anti CD-IIa, ↓T cell migration

39

anti CD-IIa, ↓T cell migration

Efalizumab

40

Indications: Efalizumab

AI disease

41

MOA: Anti-thymocyte globulin

(rabbit), modulates T cell activation and migration, ↓lymphocytes

42

(rabbit), modulates T cell activation and migration, ↓lymphocytes

Anti-thymocyte globulin

43

Indications: Anti-thymocyte globulin

Acute transplant rejection

44

MOA: Methotrexate

Inhibits DHFR, anti-proliferative agent

45

Inhibits DHFR, anti-proliferative agent

Methotrexate

46

Indications: Methotrexate

RhA, psoriasis, Crohn's, chemo, abortifacient

47

MOA: Cyclophosphamide

alkylates guanine bases of DNA
B>T cells
Anti-proliferative agent

48

alkylates guanine bases of DNA
B>T cells
Anti-proliferative agent

Cyclophosphamide

49

Indications: Cyclophosphamide

Connetive tissue disease, vasculitis with end organ damage

50

MOA: Azathioprine

Blocks purine synthesis
T cells
Anti-metabolic, (converted to 6-mercaptopurine)
Anti-proliferative agent

51

Blocks purine synthesis
T cells
Anti-metabolic, (converted to 6-mercaptopurine)
Anti-proliferative agent

Azathioprine

52

Indications: Azathioprine

Transplant, AI disease, auto-inflammatory diseases (eg. Crohn's disease, UC)

53

MOA: Mycophenolate Mofetil

Inhibits IM PDH, blocks nucleotide synthesis
T>B cells
Anti-proliferative agent

54

Inhibits IM PDH, blocks nucleotide synthesis
T>B cells
Anti-proliferative agent

Mycophenolate Mofetil

55

Indications: Mycophenolate Mofetil

2nd line for transplant, AI disease, vasculitis

56

MOA: Infliximab

anti-TNFa

57

MOA: Adalimumab

anti-TNFa

58

MOA: Certolizumab

anti-TNFa

59

MOA: Golimumab

anti-TNFa

60

anti-TNFa (x4)

Infliximab, Adalimumab, Certolizumab, Golimumab

61

Indications: Infliximab, Adalimumab, Certolizumab, Golimumab (anti-TNFa)

Psoriasis, psoriatic arthritis, IBD, RhA, ank spond

62

MOA: Etanercept

Inhibits TNFa and TNFB

63

Inhibits TNFa and TNFB

Etanercept

64

Indications: Etanercept

Psoriasis, psoriatic arthritis, IBD, RhA, ank spond

65

MOA: Ustekinumab

ab inhibits IL-12 and IL-23

66

ab inhibits IL-12 and IL-23

Ustekinumab

67

Indications: Ustekinumab

Psoriasis, psoriatic arthritis, Crohn's

68

MOA: Secukinumab

ab vs. IL17A

69

ab vs. IL17A

Secukinumab

70

Indications: Secukinumab

Ank spond, psoriasis, psoriatic arthritis,

71

MOA: Denosumab

ab vs. RANK ligand, ↓osteoclasts

72

ab vs. RANK ligand, ↓osteoclasts

Denosumab

73

Indications: Denusumab

Osteoporosis

74

MOA: Ipilimumab

mab vs CTLA4
*Boosts immune system by blocking checkpoints, ↑T cell activation*

75

mab vs CTLA4
*Boosts immune system by blocking checkpoints*

Ipilimumab

76

Indications: Ipilimumab

Advanced melanoma

77

MOA: Pemibrolizumab/Nivolumab

ab vs. PD-1
*Boosts immune system by blocking checkpoints, ↑T cell activation*

78

ab vs. PD-1
*Boosts immune system by blocking checkpoints, ↑T cell activation*

Pemibrolizumab/Nivolumab

79

Indications: Pemibrolizumab/Nivolumab

Advanced melanoma